SARS-CoV 2 Clinical Trial
Official title:
The Safety of EIDD-2801 and Its Effect on Viral Shedding of SARS-CoV-2
Designed as a multi-center, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of EIDD-2801 on SARS-CoV-2 Virus Shedding in Newly Hospitalized Adults with polymerase chain reaction (PCR)-Confirmed COVID-19.
Phase 2a randomized, placebo-controlled, double-blinded clinical trial of EIDD-2801 (also known as MK 4482) in adult men and women who have tested positive for severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection by polymerase chain reaction (PCR) test within 6 days (144 hours) prior to randomization and are hospitalized with a diagnosis of COVID-19. Rapid enrollment and treatment will be initiated such that the first dose of EIDD-2801 or placebo will be administered as soon as possible and within 7 days of onset of symptoms. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04410510 -
P2Et Extract in the Symptomatic Treatment of Subjects With COVID-19
|
Phase 2/Phase 3 | |
| Withdrawn |
NCT04456426 -
Characteristics of Patients With COVID-19 in Meta State, Colombia
|
||
| Terminated |
NCT04435457 -
Cardiovascular Implications of COVID-19
|
||
| Suspended |
NCT04385771 -
Cytokine Adsorption in Patients With Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation
|
N/A | |
| Withdrawn |
NCT04386447 -
Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19
|
Phase 2 | |
| Completed |
NCT04357834 -
WAVE. Wearable-based COVID-19 Markers for Prediction of Clinical Trajectories
|
||
| Completed |
NCT04405934 -
COG-UK Project Hospital-Onset COVID-19 Infections Study
|
N/A | |
| Completed |
NCT04615936 -
Nasal Photodisinfection COVID-19 Proof of Concept Study
|
N/A | |
| Completed |
NCT04369794 -
COVID-19: BCG As Therapeutic Vaccine, Transmission Limitation, and Immunoglobulin Enhancement
|
Phase 4 | |
| Terminated |
NCT04401410 -
Anti-SARS Cov-2 T Cell Infusions for COVID 19
|
Phase 1 | |
| Completed |
NCT04542850 -
Pilot Study to Evaluate the Safety, Tolerability, and Efficacy of 5-ALA-Phosphate + SFC in Subjects With COVID-19
|
N/A | |
| Completed |
NCT04382040 -
A Phase II, Controlled Clinical Study Designed to Evaluate the Effect of ArtemiC in Patients Diagnosed With COVID-19
|
Phase 2 | |
| Completed |
NCT04378582 -
Characteristics and Outcomes of Patients With COVID-19 Admitted to the ICU
|
||
| Completed |
NCT04366908 -
Prevention and Treatment With Calcifediol of COVID-19 Induced Acute Respiratory Syndrome
|
Phase 2 | |
| Completed |
NCT04383587 -
Seroprevalence of SARS CoV 2 Antibodies in Previously Undiagnosed Healthcare Workers
|
N/A | |
| Recruiting |
NCT04402814 -
IgG/IgM Antibody Test in Patients Who Have Tested Negative or Positive for COVID-19 With the Standard Method of COVID19 Testing.
|
||
| Completed |
NCT04374565 -
Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia
|
Phase 2 | |
| Completed |
NCT04425889 -
COVID-19 Antibodies Among Healthcare Workers
|
||
| Completed |
NCT04395924 -
Maternal-foetal Transmission of SARS-Cov-2
|
||
| Completed |
NCT04413071 -
Cardiac COVID-19 Health Care Workers
|